Entrada Therapeutics, Inc.(TRDA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Entrada Therapeutics, Inc. (TRDA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRDA at 7.3/100 on a 32-signal composite quality model, placing it at rank #2,948 of 2,962 stocks — the bottom half of the AI-ranked universe. TRDA scores in the top quartile across institutional flow (77.3). Areas of concern include revenue growth (0.3) and free cash flow (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Entrada Therapeutics, Inc. reports quarterly revenue of $898.0K, net income of $-42.8M, free cash flow of $-32.5M. Top institutional holders of TRDA by reported 13-F value include BAKER BROS. ADVISORS, 5AM Venture Management, BlackRock, based on the most recent SEC filings. TRDA trades on the Nasdaq exchange and files with the SEC under CIK 1689375. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entrada Therapeutics, Inc. directly from SEC EDGAR.